Centessa Pharmaceuticals PLC ADR (CNTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Centessa Pharmaceuticals PLC ADR (CNTA) has a cash flow conversion efficiency ratio of -0.148x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-72.22 Million) by net assets ($487.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Centessa Pharmaceuticals PLC ADR for the company's overall valuation and market capitalisation.
Centessa Pharmaceuticals PLC ADR - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Centessa Pharmaceuticals PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Centessa Pharmaceuticals PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Centessa Pharmaceuticals PLC ADR ranked by their cash flow conversion efficiency. See Centessa Pharmaceuticals PLC ADR (CNTA) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New China Life Insurance Company Ltd
F:NCL
|
0.221x |
|
MERUS N.V. EO -09
F:2GH
|
N/A |
|
Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság
F:MGYB
|
0.097x |
|
Soochow Securities Co Ltd
SHG:601555
|
0.336x |
|
Nice Ltd ADR
NASDAQ:NICE
|
0.049x |
|
Matador Resources Company
NYSE:MTDR
|
0.150x |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
-1.997x |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
0.025x |
Annual Cash Flow Conversion Efficiency for Centessa Pharmaceuticals PLC ADR (2019–2025)
The table below shows the annual cash flow conversion efficiency of Centessa Pharmaceuticals PLC ADR from 2019 to 2025. View current stock price of Centessa Pharmaceuticals PLC ADR for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $526.86 Million | $-193.82 Million | -0.368x | -3.99% |
| 2024-12-31 | $401.55 Million | $-142.06 Million | -0.354x | +47.88% |
| 2023-12-31 | $236.24 Million | $-160.34 Million | -0.679x | -13.77% |
| 2022-12-31 | $336.17 Million | $-200.55 Million | -0.597x | -115.40% |
| 2021-12-31 | $491.55 Million | $-136.14 Million | -0.277x | +91.93% |
| 2020-12-31 | $3.10 Million | $-10.63 Million | -3.431x | -704.88% |
| 2019-12-31 | $13.66 Million | $-5.83 Million | -0.426x | -- |
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more